

AMENDMENTS TO THE CLAIMS

Claims 1-22 (canceled).

Claim 23 (new): A method for treating prostate cancer, comprising administering to a patient having prostate cancer a conjugate comprising bismuth-213 or actinium-225 and an antibody specific for prostate cancer cells.

Claim 24 (new): The method of claim 23, wherein the specific activity of the bismuth-213 conjugate is about 20 mCi/mg or about 30 mCi/mg.

Claim 25 (new): The method of claim 23, wherein the specific activity of the actinium-225 conjugate is about 0.0012 mCi/mg or about 0.12 mCi/mg.

Claim 26 (new): The method of claim 23, wherein the conjugate is administered at a dose from about 0.1 mg/m² to about 10 mg/m².

Claim 27 (new): The method of claim 23, wherein the conjugate is administered intravenously.